Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
Date:4/30/2008

stemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society of America (IDSA) guidelines. This third and final phase 2 trial will investigate the product for the prevention of diabetic foot infections.

Chronic ulcerations are often colonized or contaminated with bacterial pathogens that can prevent ulcers from healing. Many such wounds become clinically infected and require treatment with antibiotics. However, early diagnosis of diabetic foot infections is a clinical challenge as typical signs and symptoms of infection, such as pain, redness, or elevated circulating inflammatory markers, can be absent in individuals with neuropathic or neuroischaemic ulcers. Failure to diagnose and treat such infections can lead rapidly to the infection spreading, with the possibility of tissue necrosis, gangrene, osteomyelitis, and ultimately the prospect of a lower leg amputation.

Currently there are no antibiotics on the market specifically indicated for the prevention of diabetic foot infections. There is also reluctance by practitioners to use existing, systemically-acting antibiotics prophylactically because of concerns with systemic side effects and fear of propagating bacterial resistance with widespread use. Furthermore, diabetic ulcers are often associated with vascular disease and restricted peripheral blood flow, which may render systemically acting antibiotics less effective. By achieving very high localized concentrations of antibiotic, CollaRx GENTAMICIN TOPICAL is designed to overcome these concerns and this trial has received support from leading podiatrists and infectious disease specialists in the US as the first of its kind. Market research independently performed by L.E.K. Consulting has forecast peak annual US sales revenues for CollaRx GENTAMICIN TOPICAL approaching US$270 million, when limiting the sales projections to diabetic foot indications only.

Dr. Michael Myers, Innocoll's P
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
2. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
6. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
7. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
8. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
9. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
10. XTENT Announces First Quarter 2008 Financial Results
11. Neuralstem Announces Issuance of Core Technology Patent in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its commitment ... (NYSE: PHG AEX: PHIA) today ... Administration (FDA) for its IQon Spectral CT , ... first-of-its kind technology adds a new dimension to Computed ... ability to characterize structures based on their material content ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... Louisiana Back Institute, leaders of ... minimally invasive spine surgery, announces today the addition ... growing provider network of orthopedic spine surgeons and ... the network’s continuing success providing the most innovative ... who are suffering from orthopedic spine conditions and ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
(Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... , , , , ... Inc. (NYSE: DVA ), a leading provider of kidney ... announced its nocturnal dialysis patient population has reached a milestone, with ... DaVita(R) centers around the nation. DaVita has one of the largest ...
... , WASHINGTON, Aug. 28 The Catholic Health ... a goal of health coverage for all people in the United ... under consideration. , , "Our message has always ... office of the association. "Health care must respect and protect human ...
... after, and protect liver from damage, experts say , FRIDAY, ... lots of water, get plenty of rest -- and eat ... the amino acids and minerals in asparagus extract may ease ... , Researchers at the Institute of Medical Science and Jeju ...
... disease, research shows , FRIDAY, Aug. 28 (HealthDay News) -- ... help doctors identify patients at high risk of suffering another ... in the ankle to that in the arm. A significant ... suffers from peripheral artery disease, caused by fatty plaque buildup ...
... Our vocabulary continues to grow and expand even in adulthood. Just ... and now we no longer remember when we heard this word ... some stage new words become just as familiar to us as ... in the Academy of Finland,s Neuroscience Research Programme (NEURO) is how ...
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
Cached Medicine News:Health News:DaVita Offers Dialysis While Patients Sleep 2Health News:DaVita Offers Dialysis While Patients Sleep 3Health News:Catholic Health Association Reaffirms Long-Standing Commitment to Reform Health Care But Waits to Endorse Any Specific Bill 2Health News:Asparagus May Ease Hangover 2Health News:Ankle Circulation Could Warn of Future Strokes 2Health News:Familiar and newly learned words are processed by the same neural networks in the brain 2
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: